Decorin deficiency promotes hepatic carcinogenesis

Matrix Biology

Volumn 35, Issue , 2014, Pages 194-205

  Horváth, Zsolt ^a   Kovalszky, Ilona ^a   Fullár, Alexandra ^a   Kiss, Katalin ^a   Schaff, Zsuzsa ^a   Iozzo, Renato V ^b   Baghy, Kornélia ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

C Myc; Cell signaling; Hepatocarcinogenesis; MSPR RON; Receptor tyrosine kinase; Small leucine rich proteoglycan; Catenin

Indexed keywords

BETA CATENIN; CARCINOGEN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DECORIN; DIETHYLNITROSAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN P21; RETINOBLASTOMA PROTEIN; SOMATOMEDIN C RECEPTOR; THIOACETAMIDE; CDKN1A PROTEIN, MOUSE; EGFR PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PROTEIN TYROSINE KINASE; SOMATOMEDIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STEADY STATE; ANIMAL; BIOLOGICAL MODEL; CARCINOGENESIS; DEFICIENCY; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALIA;

ANIMALS; BLOTTING, WESTERN; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DECORIN; DIETHYLNITROSAMINE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MODELS, BIOLOGICAL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTORS, SOMATOMEDIN; STATISTICS, NONPARAMETRIC; THIOACETAMIDE;

EID: 84901415560     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2013.11.004     Document Type: Article

References (97)

1. Araki K., Wakabayashi H., Shintani K., Morikawa J., Matsumine A., Kusuzaki K., Sudo A., Uchida A. Decorin suppresses bone metastasis in a breast cancer cell line. Oncology 2009, 77:92-99.
2. Baghy K., Dezso K., Laszlo V., Fullar A., Peterfia B., Paku S., Nagy P., Schaff Z., Iozzo R.V., Kovalszky I. Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab. Invest. 2011, 91:439-451.
3. Baghy K., Horvath Z., Regos E., Kiss K., Schaff Z., Iozzo R.V., Kovalszky I. Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis. FEBS J. 2013, 280:2150-2164.
4. Becker F.F. Thioacetamide hepatocarcinogenesis. J. Natl. Cancer Inst. 1983, 71:553-558.
5. Berasain C., Perugorria M.J., Latasa M.U., Castillo J., Goni S., Santamaria M., Prieto J., Avila M.A. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp. Biol. Med. 2009, 234:713-725.
6. Bertino G., Ardiri A., Malaguarnera M., Malaguarnera G., Bertino N., Calvagno G.S. Hepatocellular carcinoma serum markers. Semin. Oncol. 2012, 39:410-433.
7. Bi X., Tong C., Dockendorff A., Bancroft L., Gallagher L., Guzman G., Iozzo R.V., Augenlicht L.H., Yang W. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 2008, 29:1435-1440.
8. Bi X., Pohl N.M., Qian Z., Yang G.R., Gou Y., Guzman G., Kajdacsy-Balla A., Iozzo R.V., Yang W. Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis 2012, 33:326-330.
9. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
10. Brandan E., Gutierrez J. Role of skeletal muscle proteoglycans during myogenesis. Matrix Biol. 2013, 32:289-297.
11. Buraschi S., Pal N., Tyler-Rubinstein N., Owens R.T., Neill T., Iozzo R.V. Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels. J. Biol. Chem. 2010, 285:42075-42085.
12. Buraschi S., Neill T., Owens R.T., Iniguez L.A., Purkins G., Vadigepalli R., Evans B., Schaefer L., Peiper S.C., Wang Z.X., Iozzo R.V. Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model. PloS One 2012, 7:e45559.
13. Buraschi S., Neill T., Goyal A., Poluzzi C., Smythies J., Owens R.T., Schaefer L., Torres A., Iozzo R.V. Decorin causes autophagy in endothelial cells via Peg3. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E2582-E2591.
14. Camus-Randon A.M., Raffalli F., Bereziat J.C., McGregor D., Konstandi M., Lang M.A. Liver injury and expression of cytochromes P450: evidence that regulation of CYP2A5 is different from that of other major xenobiotic metabolizing CYP enzymes. Toxicol. Appl. Pharmacol. 1996, 138:140-148.
15. Chen S., Birk D.E. The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly. FEBS J. 2013, 280:2120-2137.
16. Chen Q., Seol D.W., Carr B., Zarnegar R. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 1997, 26:59-66.
17. Chen X.H., Li Z.Q., Peng H., Jin S.M., Fu H.Q., Zhu T.C., Weng X.G. Type 1 insulin-like growth factor receptor monoclonal antibody (HX-1162) treatment for liver cancer. OncoTargets Ther. 2013, 6:527-530.
18. Cho S.B., Park Y.L., Song Y.A., Kim K.Y., Lee G.H., Cho D.H., Myung D.S., Park K.J., Lee W.S., Chung I.J., Choi S.K., Kim K.K., Joo Y.E. Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells. Oncol. Rep. 2011, 26:1581-1586.
19. Csordas G., Santra M., Reed C.C., Eichstetter I., McQuillan D.J., Gross D., Nugent M.A., Hajnoczky G., Iozzo R.V. Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J. Biol. Chem. 2000, 275:32879-32887.
20. Dahmani R., Just P.A., Perret C. The Wnt/beta-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clinics and research in hepatology and gastroenterology 35 2011, 709-713.
21. Daley W.P., Peters S.B., Larsen M. Extracellular matrix dynamics in development and regenerative medicine. J. Cell Sci. 2008, 121:255-264.
22. Danielson K.G., Baribault H., Holmes D.F., Graham H., Kadler K.E., Iozzo R.V. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell Biol. 1997, 136:729-743.
23. Danilkovitch-Miagkova A., Miagkov A., Skeel A., Nakaigawa N., Zbar B., Leonard E.J. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol. Cell. Biol. 2001, 21:5857-5868.
24. De Luca A., Santra M., Baldi A., Giordano A., Iozzo R.V. Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J. Biol. Chem. 1996, 271:18961-18965.
25. Dudas J., Kovalszky I., Gallai M., Nagy J.O., Schaff Z., Knittel T., Mehde M., Neubauer K., Szalay F., Ramadori G. Expression of decorin, transforming growth factor-beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis. Am. J. Clin. Pathol. 2001, 115:725-735.
26. Dunkman A.A., Buckley M.R., Mienaltowski M.J., Adams S.M., Thomas S.J., Satchell L., Kumar A., Pathmanathan L., Beason D.P., Iozzo R.V., Birk D.E., Soslowsky L.J. Decorin expression is important for age-related changes in tendon structure and mechanical properties. Matrix Biol. 2013, 32:3-13.
27. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
28. Farber E. The multistep nature of cancer development. Cancer Res. 1984, 44:4217-4223.
29. Ferdous Z., Peterson S.B., Tseng H., Anderson D.K., Iozzo R.V., Grande-Allen K.J. A role for decorin in controlling proliferation, adhesion, and migration of murine embryonic fibroblasts. J. Biomed. Mater. Res. A 2010, 93:419-428.
30. Goldoni S., Seidler D.G., Heath J., Fassan M., Baffa R., Thakur M.L., Owens R.T., McQuillan D.J., Iozzo R.V. An antimetastatic role for decorin in breast cancer. Am. J. Pathol. 2008, 173:844-855.
31. Goldoni S., Humphries A., Nystrom A., Sattar S., Owens R.T., McQuillan D.J., Ireton K., Iozzo R.V. Decorin is a novel antagonistic ligand of the Met receptor. J. Cell Biol. 2009, 185:743-754.
32. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 2001, 65:391-426.
33. Guo J., Friedman S.L. Hepatic fibrogenesis. Sem. Liver Dis. 2007, 27:413-426.
34. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
35. Harper J.W., Elledge S.J., Keyomarsi K., Dynlacht B., Tsai L.H., Zhang P., Dobrowolski S., Bai C., Connell-Crowley L., Swindell E., et al. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 1995, 6:387-400.
36. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512. (New York, N.Y.).
37. Heindryckx F., Colle I., Van Vlierberghe H. Experimental mouse models for hepatocellular carcinoma research. Int. J. Exp. Pathol. 2009, 90:367-386.
38. Hielscher A.C., Qiu C., Gerecht S. Breast cancer cell-derived matrix supports vascular morphogenesis. Am. J. Physiol. Cell Physiol. 2012, 302:C1243-C1256.
39. Hu T., Li C. Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol. Cancer 2010, 9:236.
40. Hu Y., Sun H., Owens R.T., Wu J., Chen Y.Q., Berquin I.M., Perry D., O'Flaherty J.T., Edwards I.J. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 2009, 11:1042-1053.
41. Hynes R.O. The extracellular matrix: not just pretty fibrils. Science 2009, 326:1216-1219. (New York, N.Y.).
42. Ichii M., Frank M.B., Iozzo R.V., Kincade P.W. The canonical Wnt pathway shapes niches supportive of hematopoietic stem/progenitor cells. Blood 2012, 119:1683-1692.
43. Iozzo R.V. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J. Biol. Chem. 1999, 274:18843-18846.
44. Iozzo R.V., Cohen I. Altered proteoglycan gene expression and the tumor stroma. Experientia 1993, 49:447-455.
45. Iozzo R.V., Murdoch A.D. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. Faseb J. 1996, 10:598-614.
46. Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 2011, 15:1013-1031.
47. Iozzo R.V., Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J. 2010, 277:3864-3875.
48. Iozzo R.V., Chakrani F., Perrotti D., McQuillan D.J., Skorski T., Calabretta B., Eichstetter I. Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3092-3097.
49. Iozzo R.V., Moscatello D.K., McQuillan D.J., Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J. Biol. Chem. 1999, 274:4489-4492.
50. Iozzo R.V., Buraschi S., Genua M., Xu S.Q., Solomides C.C., Peiper S.C., Gomella L.G., Owens R.C., Morrione A. Decorin antagonizes IGF receptor I (IGF-IR) function by interfering with IGF-IR activity and attenuating downstream signaling. J. Biol. Chem. 2011, 286:34712-34721.
51. Jacobs K.M., Bhave S.R., Ferraro D.J., Jaboin J.J., Hallahan D.E., Thotala D. GSK-3beta: a bifunctional role in cell death pathways. Int. j. cell biol. 2012, 2012:930710.
52. Jain S., Singhal S., Lee P., Xu R. Molecular genetics of hepatocellular neoplasia. Am. J. Transl. Res. 2010, 2:105-118.
53. Jarvelainen H., Sainio A., Koulu M., Wight T.N., Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol. Rev. 2009, 61:198-223.
54. Jung P., Hermeking H. The c-MYC-AP4-p21 cascade. Cell cycle 2009, 8:982-989.
55. Khan G.A., Girish G.V., Lala N., Di Guglielmo G.M., Lala P.K. Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblast. Mol. Endocrinol. 2011, 25:1431-1443.
56. Lee J.S., Thorgeirsson S.S. Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology 2002, 35:1134-1143.
57. Lempinen M., Lyytinen I., Nordin A., Tervahartiala T., Makisalo H., Sorsa T., Isoniemi H. Prognostic value of serum MMP-8, -9 and TIMP-1 in patients with hepatocellular carcinoma. Ann. Med. 2013, 45:482-487.
58. Li Y., Liu Y., Xia W., Lei D., Voorhees J.J., Fisher G.J. Age-dependent alterations of decorin glycosaminoglycans in human skin. Sci. Rep. 2013, 3:2422.
59. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
60. Loeppen S., Schneider D., Gaunitz F., Gebhardt R., Kurek R., Buchmann A., Schwarz M. Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res. 2002, 62:5685-5688.
61. Lu J.W., Lin Y.M., Chang J.G., Yeh K.T., Chen R.M., Tsai J.J., Su W.W., Hu R.M. Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinoma. Med. Oncol. 2013, 30:379.
62. Marastoni S., Ligresti G., Lorenzon E., Colombatti A., Mongiat M. Extracellular matrix: a matter of life and death. Connect. Tissue Res. 2008, 49:203-206.
63. Merline R., Moreth K., Beckmann J., Nastase M.V., Zeng-Brouwers J., Tralhao J.G., Lemarchand P., Pfeilschifter J., Schaefer R.M., Iozzo R.V., Schaefer L. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci. Signal. 2011, 4:ra75.
64. Morrione A., Neill T., Iozzo R.V. Dichotomy of decorin activity on the insulin-like growth factor-I system. FEBS J. 2013, 280:2138-2149.
65. Neill T., Painter H., Buraschi S., Owens R.T., Lisanti M.P., Schaefer L., Iozzo R.V. Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1alpha, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. J. Biol. Chem. 2012, 287:5492-5506.
66. Neill T., Schaefer L., Iozzo R.V. Decorin: a guardian from the matrix. Am. J. Pathol. 2012, 181:380-387.
67. Neill T., Jones H.R., Crane-Smith Z., Owens R.T., Schaefer L., Iozzo R.V. Decorin induces rapid secretion of thrombospondin-1 in basal breast carcinoma cells via inhibition of Ras homolog gene family, member A/Rho-associated coiled-coil containing protein kinase 1. FEBS J. 2013, 280:2353-2368.
68. Nikitovic D., Aggelidakis J., Young M.F., Iozzo R.V., Karamanos N.K., Tzanakakis G.N. The biology of small leucine-rich proteoglycans in bone pathophysiology. J. Biol. Chem. 2012, 287:33926-33933.
69. Nystrom A., Shaik Z.P., Gullberg D., Krieg T., Eckes B., Zent R., Pozzi A., Iozzo R.V. Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin angiostatic activity. Blood 2009, 114:4897-4906.
70. Okazaki I., Inagaki Y. Novel strategies for hepatocellular carcinoma based on MMPs science. Anti Cancer Agents Med. Chem. 2012, 12:753-763.
71. Oseini A.M., Roberts L.R. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?. Expert Opin. Ther. Targets 2009, 13:443-454.
72. Reed C.C., Iozzo R.V. The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj. J. 2002, 19:249-255.
73. Reed C.C., Gauldie J., Iozzo R.V. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 2002, 21:3688-3695.
74. Reed C.C., Waterhouse A., Kirby S., Kay P., Owens R.T., McQuillan D.J., Iozzo R.V. Decorin prevents metastatic spreading of breast cancer. Oncogene 2005, 24:1104-1110.
75. Rivadeneira D.B., Mayhew C.N., Thangavel C., Sotillo E., Reed C.A., Grana X., Knudsen E.S. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology 2010, 138:1920-1930.
76. Robinson P.S., Huang T.F., Kazam E., Iozzo R.V., Birk D.E., Soslowsky L.J. Influence of decorin and biglycan on mechanical properties of multiple tendons in knockout mice. J. Biomech. Eng. 2005, 127:181-185.
77. Rozario T., DeSimone D.W. The extracellular matrix in development and morphogenesis: a dynamic view. Dev. Biol. 2010, 341:126-140.
78. Ruoslahti E., Yamaguchi Y. Proteoglycans as modulators of growth factor activities. Cell 1991, 64:867-869.
79. Santra M., Mann D.M., Mercer E.W., Skorski T., Calabretta B., Iozzo R.V. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J. Clin. Invest. 1997, 100:149-157.
80. Schaefer L., Iozzo R.V. Small leucine-rich proteoglycans, at the crossroad of cancer growth and inflammation. Curr. Opin. Genet. Dev. 2012, 22:56-57.
81. Schaefer L., Tsalastra W., Babelova A., Baliova M., Minnerup J., Sorokin L., Grone H.J., Reinhardt D.P., Pfeilschifter J., Iozzo R.V., Schaefer R.M. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin. Am. J. Pathol. 2007, 170:301-315.
82. Schonherr E., Sunderkotter C., Iozzo R.V., Schaefer L. Decorin, a novel player in the insulin-like growth factor system. J. Biol. Chem. 2005, 280:15767-15772.
83. Seidler D.G. The galactosaminoglycan-containing decorin and its impact on diseases. Curr. Opin. Struct. Biol. 2012, 22:578-582.
84. Seidler D.G., Dreier R. Decorin and its galactosaminoglycan chain: extracellular regulator of cellular function?. IUBMB life 2008, 60:729-733.
85. Seidler D.G., Mohamed N.A., Bocian C., Stadtmann A., Hermann S., Schafers K., Schafers M., Iozzo R.V., Zarbock A., Gotte M. The role for decorin in delayed-type hypersensitivity. J. Immunol. 2011, 187:6108-6119.
86. Sengupta B., Siddiqi S.A. Hepatocellular carcinoma: important biomarkers and their significance in molecular diagnostics and therapy. Curr. Med. Chem. 2012, 19:3722-3729.
87. Sherman M. Epidemiology of hepatocellular carcinoma. Oncology 2010, 78(Suppl. 1):7-10.
88. Sofeu Feugaing D.D., Gotte M., Viola M. More than matrix: the multifaceted role of decorin in cancer. Eur. J. Cell Biol. 2013, 92:1-11.
89. Stock P., Monga D., Tan X., Micsenyi A., Loizos N., Monga S.P. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol. Cancer Ther. 2007, 6:1932-1941.
90. Tralhao J.G., Schaefer L., Micegova M., Evaristo C., Schonherr E., Kayal S., Veiga-Fernandes H., Danel C., Iozzo R.V., Kresse H., Lemarchand P. In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. Faseb J. 2003, 17:464-466.
91. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., Llovet J.M. Genomics and signaling pathways in hepatocellular carcinoma. Sem. Liver Dis. 2007, 27:55-76.
92. Whittaker S., Marais R., Zhu A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29:4989-5005.
93. Wu J., Zhu A.X. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J. Hematol. Oncol. 2011, 4:30.
94. Yamaguchi Y., Mann D.M., Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990, 346:281-284.
95. Zhang G., Chen S., Goldoni S., Calder B.W., Simpson H.C., Owens R.T., McQuillan D.J., Young M.F., Iozzo R.V., Birk D.E. Genetic evidence for the coordinated regulation of collagen fibrillogenesis in the cornea by decorin and biglycan. J. Biol. Chem. 2009, 284:8888-8897.
96. Zhang Y., Wang Y., Du Z., Wang Q., Wu M., Wang X., Wang L., Cao L., Hamid A.S., Zhang G. Recombinant human decorin suppresses liver HepG2 carcinoma cells by p21 upregulation. OncoTargets Ther. 2012, 5:143-152.
97. Zhu J.X., Goldoni S., Bix G., Owens R.T., McQuillan D.J., Reed C.C., Iozzo R.V. Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J. Biol. Chem. 2005, 280:32468-32479.